Vicky Hsu1, Manuela de L T Vieira1,2, Ping Zhao3, Lei Zhang1, Jenny Huimin Zheng1, Anna Nordmark4, Eva Gil Berglund4, Kathleen M Giacomini5, Shiew-Mei Huang1. 1. Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA. 2. College of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil. 3. Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA. ping.zhao@fda.hhs.gov. 4. Swedish Medical Products Agency, Uppsala, Sweden. 5. Department of Bioengineering and Therapeutic Sciences, Schools of Pharmacy and Medicine, University of California San Francisco, San Francisco, CA, USA.
Abstract
BACKGROUND AND OBJECTIVES: The kidney is a major drug-eliminating organ. Renal impairment or concomitant use of transporter inhibitors may decrease active secretion and increase exposure to a drug that is a substrate of kidney secretory transporters. However, prediction of the effects of patient factors on kidney transporters remains challenging because of the multiplicity of transporters and the lack of understanding of their abundance and specificity. The objective of this study was to use physiologically based pharmacokinetic (PBPK) modelling to evaluate the effects of patient factors on kidney transporters. METHODS: Models for three renally cleared drugs (oseltamivir carboxylate, cidofovir and cefuroxime) were developed using a general PBPK platform, with the contributions of net basolateral uptake transport (T up,b) and apical efflux transport (T eff,a) being specifically defined. RESULTS AND CONCLUSION: We demonstrated the practical use of PBPK models to: (1) define transporter-mediated renal secretion, using plasma and urine data; (2) inform a change in the system-dependent parameter (≥10-fold reduction in the functional 'proximal tubule cells per gram kidney') in severe renal impairment that is responsible for the decreased secretory transport activities of test drugs; (3) derive an in vivo, plasma unbound inhibition constant of T up,b by probenecid (≤1 μM), based on observed drug interaction data; and (4) suggest a plausible mechanism of probenecid preferentially inhibiting T up,b in order to alleviate cidofovir-induced nephrotoxicity.
BACKGROUND AND OBJECTIVES: The kidney is a major drug-eliminating organ. Renal impairment or concomitant use of transporter inhibitors may decrease active secretion and increase exposure to a drug that is a substrate of kidney secretory transporters. However, prediction of the effects of patient factors on kidney transporters remains challenging because of the multiplicity of transporters and the lack of understanding of their abundance and specificity. The objective of this study was to use physiologically based pharmacokinetic (PBPK) modelling to evaluate the effects of patient factors on kidney transporters. METHODS: Models for three renally cleared drugs (oseltamivir carboxylate, cidofovir and cefuroxime) were developed using a general PBPK platform, with the contributions of net basolateral uptake transport (T up,b) and apical efflux transport (T eff,a) being specifically defined. RESULTS AND CONCLUSION: We demonstrated the practical use of PBPK models to: (1) define transporter-mediated renal secretion, using plasma and urine data; (2) inform a change in the system-dependent parameter (≥10-fold reduction in the functional 'proximal tubule cells per gram kidney') in severe renal impairment that is responsible for the decreased secretory transport activities of test drugs; (3) derive an in vivo, plasma unbound inhibition constant of T up,b by probenecid (≤1 μM), based on observed drug interaction data; and (4) suggest a plausible mechanism of probenecid preferentially inhibiting T up,b in order to alleviate cidofovir-induced nephrotoxicity.
Authors: George Hill; Tomas Cihlar; Charles Oo; Edmund S Ho; Ken Prior; Hugh Wiltshire; Jo Barrett; Baulian Liu; Penny Ward Journal: Drug Metab Dispos Date: 2002-01 Impact factor: 3.922
Authors: Neil Parrott; Brian Davies; Gerhard Hoffmann; Annette Koerner; Thierry Lave; Eric Prinssen; Elizabeth Theogaraj; Thomas Singer Journal: Clin Pharmacokinet Date: 2011-09 Impact factor: 6.447
Authors: Ping Zhao; Manuela de L T Vieira; Joseph A Grillo; Pengfei Song; Ta-Chen Wu; Jenny H Zheng; Vikram Arya; Eva Gil Berglund; Arthur J Atkinson; Yuichi Sugiyama; K Sandy Pang; Kellie S Reynolds; Darrell R Abernethy; Lei Zhang; Lawrence J Lesko; Shiew-Mei Huang Journal: J Clin Pharmacol Date: 2012-01 Impact factor: 3.126
Authors: M J Cutler; B L Urquhart; T J Velenosi; H E Meyer Zu Schwabedissen; G K Dresser; B F Leake; R G Tirona; R B Kim; D J Freeman Journal: J Clin Pharmacol Date: 2011-04-19 Impact factor: 3.126
Authors: Manthena V S Varma; Bo Feng; R Scott Obach; Matthew D Troutman; Jonathan Chupka; Howard R Miller; Ayman El-Kattan Journal: J Med Chem Date: 2009-08-13 Impact factor: 7.446
Authors: Daniel Scotcher; Christopher Jones; Maria Posada; Aleksandra Galetin; Amin Rostami-Hodjegan Journal: AAPS J Date: 2016-08-09 Impact factor: 4.009